Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 23, No 7 (March 1), 2005: pp. 1473-1482
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.07.168

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, D. L.
Right arrow Articles by Li, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, D. L.
Right arrow Articles by Li, G.

Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases

Derek L. Dai, Magdalena Martinka, Gang Li

From the Department of Medicine, Division of Dermatology; Department of Pathology, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.

Address reprint requests to Gang Li, MD, Jack Bell Research Centre, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada; e-mail: gangli{at}interchange.ubc.ca

PURPOSE: Akt is a serine/threonine kinase that leads to stimulation of cell cycle progression, cell proliferation, and inhibition of apoptosis. To investigate the role of Akt in melanoma pathogenesis, we examined the expression of phospho-Akt (p-Akt; Ser-473) in melanocytic lesions at different stages and analyzed the correlations between the p-Akt expression level and clinicopathologic factors and patient survival.

PATIENTS AND METHODS: We evaluated the p-Akt expression in 12 cases of normal nevi, 58 cases of dysplastic nevi, 170 cases of primary melanomas, and 52 cases of melanoma metastases using tissue microarray and immunohistochemistry.

RESULTS: Strong p-Akt expression was observed in 17%, 43%, 49%, and 77% of the biopsies in normal nevi, dysplastic nevi, primary melanoma, and melanoma metastases, respectively. Significant differences for p-Akt staining pattern were observed between normal nevi and primary melanomas (P < .05), and between primary melanomas and melanoma metastases (P < .001). Furthermore, our Kaplan-Meier survival curves showed that strong p-Akt expression is inversely correlated with both overall and disease-specific 5-year survival of patients with primary melanoma (P < .05 for both). Strikingly, our multivariate Cox regression analysis revealed that p-Akt is an independent prognostic factor in low-risk melanomas (thickness ≤ 1.5 mm; relative risk, 6.44; 95% CI, 1.28 to 32.55; P = .018).

CONCLUSION: The expression of p-Akt increases dramatically with melanoma invasion and progression and is inversely correlated with patient survival. In addition, p-Akt may serve as an independent prognostic marker and help to identify those patients with low-risk melanomas who are at increased risk of death.

Supported by the National Cancer Institute of Canada.

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
T. Sittler, J. Zhou, J. Park, N. K. Yuen, S. Sarantopoulos, J. Mollick, R. Salgia, A. Giobbie-Hurder, G. Dranoff, and F. S. Hodi
Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity
Clin. Cancer Res., June 15, 2008; 14(12): 3896 - 3905.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Cheung, A. Sharma, S. V. Madhunapantula, and G. P. Robertson
Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development
Cancer Res., May 1, 2008; 68(9): 3429 - 3439.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Jiang, A. Enomoto, M. Jijiwa, T. Kato, T. Hasegawa, M. Ishida, T. Sato, N. Asai, Y. Murakumo, and M. Takahashi
An Actin-Binding Protein Girdin Regulates the Motility of Breast Cancer Cells
Cancer Res., March 1, 2008; 68(5): 1310 - 1318.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Crowell, V. E. Steele, and J. R. Fay
Targeting the AKT protein kinase for cancer chemoprevention
Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Wang, D. L. Dai, M. Martinka, and G. Li
Prognostic Significance of Nuclear ING3 Expression in Human Cutaneous Melanoma
Clin. Cancer Res., July 15, 2007; 13(14): 4111 - 4116.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. M. Karst, D. L. Dai, J. Q. Cheng, and G. Li
Role of p53 Up-regulated Modulator of Apoptosis and Phosphorylated Akt in Melanoma Cell Growth, Apoptosis, and Patient Survival.
Cancer Res., September 15, 2006; 66(18): 9221 - 9226.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Gao, D. L. Dai, M. Martinka, and G. Li
Prognostic Significance of Nuclear Factor-{kappa}B p105/p50 in Human Melanoma and Its Role in Cell Migration.
Cancer Res., September 1, 2006; 66(17): 8382 - 8388.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. S. Spofford, E. V. Abel, K. Boisvert-Adamo, and A. E. Aplin
Cyclin D3 Expression in Melanoma Cells Is Regulated by Adhesion-dependent Phosphatidylinositol 3-Kinase Signaling and Contributes to G1-S Progression
J. Biol. Chem., September 1, 2006; 281(35): 25644 - 25651.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
R Bauer, P J Wild, S Meyer, F Bataille, A Pauer, M Klinkhammer-Schalke, F Hofstaedter, and A K Bosserhoff
Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays
J. Clin. Pathol., July 1, 2006; 59(7): 699 - 705.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Tsurutani, J. Fukuoka, H. Tsurutani, J. H. Shih, S. M. Hewitt, W. D. Travis, J. Jen, and P. A. Dennis
Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non-Small-Cell Lung Cancer Tumors
J. Clin. Oncol., January 10, 2006; 24(2): 306 - 314.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online